BIOCON GETS DCGI NOD FOR CANCER DRUG

Biotechnology major Biocon has got the Drug and Controller General of India (DCGI) approval for marketing its BIOMAb EGFR in the Indian market. This is a proprietary product of Biocon, which will be used in treating head and neck cancers.

Pipeline Review (http://www.pipelinereview.com/joomla/content/view/5347/102/)